Asthma Clinical Trial
Official title:
Modification of Asthma With Soy Isoflavone
The purpose of this study is to determine if dietary supplementation with soy isoflavones in persistent asthma improves airway reactivity as determined by PC20 to methacholine.
Asthma is a complex disease whose prevalence and severity are determined by multiple genetic
and environmental factors. The prevalence of asthma has increased during the past few
decades. Although causal relationships have not been proven, changing dietary practices have
paralleled the increase in asthma prevalence. Several surveys have found an association
between reduced lung function and decreased consumption of antioxidants, flavonoids, and
essential vitamins in a variety of respiratory conditions including asthma. These findings
suggest that diet may be a factor that impacts asthma and its clinical manifestations.
Higher dietary consumption of soy isoflavones is associated with decreased self-report of
cough and other allergic respiratory symptoms. Our group reported an inverse relationship
between dietary intake of the soy isoflavone genistein and asthma severity. In addition, we
recently demonstrated that genistein inhibits synthesis of cysteinyl-leukotrienes in
eosinophils by blocking p38-dependent activation of 5-lipoxygenase, providing a plausible
cellular mechanism for the benefit of soy isoflavones in asthma. We also documented that
dietary soy isoflavone supplementation in asthma patients inhibited eosinophil
cysteinyl-leukotriene synthesis and decreased exhaled nitric oxide, an indicator of
eosinophilic airway inflammation. Our overall long-term goal is to translate these
epidemiological and mechanistic findings to human disease and determine whether dietary soy
isoflavones have a clinical role in asthma. We propose a clinical study powered to detect an
improvement in lung function as the first stop in achieving this goal.
Our hypothesis is that dietary supplementation with isoflavones will improve lung function,
reduce symptoms, and decrease airway inflammation in asthma. To test this, we will conduct a
randomized placebo-controlled, cross-over study of soy isoflavone supplementation in
patients with persistent asthma.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|